Literature DB >> 31225840

Management of Androgen Deprivation Therapy-Associated Hot Flashes in Men With Prostate Cancer.

Yousef Qan'ir1, Darrell DeDeaux2, Paul A Godley1, Deborah K Mayer3, Lixin Song1.   

Abstract

PROBLEM IDENTIFICATION: To determine best practices for managing hot flashes associated with androgen deprivation therapy (ADT) in men with prostate cancer. LITERATURE SEARCH: The CINAHL®, Embase®, PsycINFO®, PubMed®, and Scopus® databases were used to identify randomized controlled trials (RCTs) and quasiexperimental studies published between January 1994 and June 2018. DATA EVALUATION: Using the Cochrane Handbook for Systematic Reviews of Interventions, the authors reviewed 15 studies examining the effects of pharmacologic or complementary and alternative medicine interventions on ADT-associated hot flashes in men with prostate cancer. SYNTHESIS: Pharmacologic interventions (e.g., cyproterone, medroxyprogesterone, megestrol acetate) showed some promise for reducing hot flashes but were associated with side effects and risks. Acupuncture demonstrated potential benefit in reducing hot flashes without side effects. IMPLICATIONS FOR RESEARCH: Evidence is insufficient to support interventions for ADT-associated hot flashes in men with prostate cancer. Future RCTs should be sufficiently powered, include a control group, and use standardized outcome measures.

Entities:  

Keywords:  androgen deprivation therapy; complementary and alternative medicine; hot flashes

Mesh:

Substances:

Year:  2019        PMID: 31225840     DOI: 10.1188/19.ONF.E107-E118

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  1 in total

1.  Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses.

Authors:  Brian Hutton; Mona Hersi; Wei Cheng; Misty Pratt; Pauline Barbeau; Sasha Mazzarello; Nadera Ahmadzai; Becky Skidmore; Scott C Morgan; Louise Bordeleau; Pamela K Ginex; Behnam Sadeghirad; Rebecca L Morgan; Katherine Marie Cole; Mark Clemons
Journal:  Oncol Nurs Forum       Date:  2020-07-01       Impact factor: 2.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.